P Bergmann

Summary

Affiliation: CHU Brugmann
Country: Belgium

Publications

  1. pmc Loading and skeletal development and maintenance
    P Bergmann
    Department of Nuclear Medicine, Laboratory of Clinical Chemistry and Experimental Medicine, CHU Brugmann, Universite Libre de Bruxelles, 4 Pl Van Gehuchten, 1020 Brussels, Belgium
    J Osteoporos 2011:786752. 2010
  2. pmc Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled trial
    Ingo Beyer
    Department of Geriatrics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B 1090 Brussels, Belgium
    BMC Musculoskelet Disord 12:292. 2011
  3. pmc Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
    P Bergmann
    Laboratory of Clinical Chemistry, CHU Brugmann, Universite Libre de Bruxelles, Bruxelles, Belgium
    Int J Clin Pract 63:19-26. 2009
  4. ncbi [Clinical use of biological markers of bone turnover in osteoporosis]
    P Bergmann
    Service de Diagnostic et de Traitement par Isotopes et Laboratoires de Chimie Clinique et de Médecine Expérimentale, C H U Brugmann, Bruxelles
    Rev Med Brux 29:295-300. 2008
  5. pmc Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 23:S1-23. 2012
  6. pmc Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 21:1657-80. 2010
  7. ncbi Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann and Institute J Bordet, Universite Libre de Bruxelles, 4 Place Van Gehuchten, Brussels 1020, Belgium
    Osteoporos Int 18:1439-50. 2007
  8. doi Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease
    M Mesquita
    Clinic of Nephrology, CHU Brugmann, Brussels, Belgium
    Transplant Proc 42:3444-9. 2010
  9. ncbi Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients
    V Huyge
    Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium
    Clin Oncol (R Coll Radiol) 22:818-27. 2010
  10. ncbi [Absolute risk fracture prediction by risk factors validation and survey of osteoporosis in a Brussels cohort followed during 10 years (FRISBEE study)]
    J J Body
    Service de Medecine Interne, C H U Brugmann, Bruxelles
    Rev Med Brux 29:289-93. 2008

Collaborators

Detail Information

Publications13

  1. pmc Loading and skeletal development and maintenance
    P Bergmann
    Department of Nuclear Medicine, Laboratory of Clinical Chemistry and Experimental Medicine, CHU Brugmann, Universite Libre de Bruxelles, 4 Pl Van Gehuchten, 1020 Brussels, Belgium
    J Osteoporos 2011:786752. 2010
    ..The most practical advice for patients is to walk a minimum of 30 to 60 minutes per day. Other exercises like swimming or cycling have less effect on bone, but could reduce fracture risk indirectly by maintaining muscle mass and force...
  2. pmc Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled trial
    Ingo Beyer
    Department of Geriatrics, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, B 1090 Brussels, Belgium
    BMC Musculoskelet Disord 12:292. 2011
    ..We hypothesized that NSAID treatment would preserve muscle performance better than antibiotic treatment alone, by reducing infection-associated inflammation and by increasing expression of cytoprotective Hsp...
  3. pmc Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club
    P Bergmann
    Laboratory of Clinical Chemistry, CHU Brugmann, Universite Libre de Bruxelles, Bruxelles, Belgium
    Int J Clin Pract 63:19-26. 2009
    ....
  4. ncbi [Clinical use of biological markers of bone turnover in osteoporosis]
    P Bergmann
    Service de Diagnostic et de Traitement par Isotopes et Laboratoires de Chimie Clinique et de Médecine Expérimentale, C H U Brugmann, Bruxelles
    Rev Med Brux 29:295-300. 2008
    ..It allows also to predict the effect of treatment in terms of bone gain and fracture risk reduction, and to encourage the patient to persist with the treatment in the long run...
  5. pmc Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 23:S1-23. 2012
    ..Drugs used for the prevention and the treatment of osteoporosis exert various favourable and unfavourable extra-skeletal effects whose importance is increasingly recognized notably for treatment selection...
  6. pmc Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 21:1657-80. 2010
    ..It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect...
  7. ncbi Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann and Institute J Bordet, Universite Libre de Bruxelles, 4 Place Van Gehuchten, Brussels 1020, Belgium
    Osteoporos Int 18:1439-50. 2007
    ..Bisphosphonate treatment should be considered in osteoporotic but also in osteopenic patients if other risk factor(s) for fractures are present...
  8. doi Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease
    M Mesquita
    Clinic of Nephrology, CHU Brugmann, Brussels, Belgium
    Transplant Proc 42:3444-9. 2010
    ..Longer follow-up of these patients would be necessary to assess whether a decline in OPG correlates with better survival...
  9. ncbi Heterogeneity of metabolic response to systemic therapy in metastatic breast cancer patients
    V Huyge
    Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium
    Clin Oncol (R Coll Radiol) 22:818-27. 2010
    ....
  10. ncbi [Absolute risk fracture prediction by risk factors validation and survey of osteoporosis in a Brussels cohort followed during 10 years (FRISBEE study)]
    J J Body
    Service de Medecine Interne, C H U Brugmann, Bruxelles
    Rev Med Brux 29:289-93. 2008
    ..05) relationship between diagnosis of osteoporosis at DXA and the number of risk factors, age > 70 years, a personal history of fracture after 50 years and a BMI < 20...
  11. ncbi [Blood tests and imaging in thyroid pathology]
    P Bergmann
    Services de Diagnostic et de Traitement par Isotopes, C H U Brugmann, Bruxelles
    Rev Med Brux 33:246-53. 2012
    ..Whole body scintigraphy is mandatory after radioiodine treatment with 131I in order to visualize possible metastasis and establish their avidity for iodine...
  12. ncbi Quantitative ultrasound and dual X-ray absorptiometry measurements of the calcaneus in patients on maintenance hemodialysis
    A Peretz
    Clinic of Rheumatology, CHU Brugmann, Brussels, Belgium
    Bone 27:287-92. 2000
    ..The clinical relevance of this finding is presently unclear...
  13. ncbi Effects of CGRP on human osteoclast-like cell formation: a possible connection with the bone loss in neurological disorders?
    A Akopian
    Laboratory of Experimental Hematology, at CHU Brugmann, Universite Libre de Bruxelles, 4 Place Van Gehuchten, 1020 Brussels, Belgium
    Peptides 21:559-64. 2000
    ..We therefore investigated in this study the effects of CGRP on human OCL-like formation and found that it indeed has an inhibitory effect mediated at least in part via cAMP...